Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227434 · ClinicalTrials.gov registry record · Phase 2
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01227434 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 23 participants.
The verdict
NCT01227434, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study will determine the efficacy of the small molecule CDK4/6 inhibitor PD 0332991 (as measured by progression free survival at 6 months) in patients with recurrent glioblastoma multiforme or gliosarcoma who are Rb positive. A total of 30 patients will be treated; 15 will undergo a planned surgical resection and receive drug for 7 days prior to surgery, followed by drug after recovery from surgery, and the other 15 patients will receive drug without a planned surgical procedure.
Interventions
- DRUG PD 0332991
- DRUG PD 0332991 (pre-surgery)
- PROCEDURE Resection as clinical care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01227434
The ClinicalTrials.gov registry entry for NCT01227434 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PD 0332991 is the first listed.
NCT01227434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01227434 about?
NCT01227434 is a clinical study titled "A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma". This study will determine the efficacy of the small molecule CDK4/6 inhibitor PD 0332991 (as measured by progression free survival at 6 months) in patients with recurrent glioblastoma multiforme or gliosarcoma who are Rb positive. A total of 30 patients will be treated; 15 will undergo a planned sur...
What is the current status of trial NCT01227434?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2010-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01227434?
The interventions under investigation include: PD 0332991 (DRUG), PD 0332991 (pre-surgery) (DRUG), Resection as clinical care (PROCEDURE).
Who is sponsoring clinical trial NCT01227434?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.